非侵入性眼后段给药的纳米药物递送策略研究进展
|
摘要
由于眼睛独特的生理结构,常规眼局部给药用于眼后段疾病的治疗一直是困扰医药工作者的一大难题。基于纳米递送策略研发的眼部给药系统因具有尺寸小、渗透性强、对生物膜表面黏附性强等特点,有望发展成为安全、有效、经济和无创的新型眼部药物输送系统,特别在眼后段给药中越来越受到重视。本文重点介绍非侵入性眼后段给药的各类纳米药物递送策略,包括纳米粒、脂质体、纳米胶束、纳米悬浮液和纳米乳等给药系统。
Because of the unique physiological structure of eyes, routine eye topical administration for the treatment of posterior eye disease has always been a difficult problem for medical workers. The developed drug delivery system of eyes based on nano-drug delivery strategy has characters of small size, strong penetration, strong surface adhesion for biofilm, and so on, which is expected to develop into a safe, effective, economical and non-invasive new eye drug delivery system, in particular, more and more attention has been paid to drug administration in the posterior eye segment.This paper focuses on the various nano-drug delivery strategies of non-invasive drug administration of the posterior eye segment, including drug delivery systems of nanoparticles, lipidosome, nano-micelle, nano suspensions and nanoemulsion.
Because of the unique physiological structure of eyes, routine eye topical administration for the treatment of posterior eye disease has always been a difficult problem for medical workers. The developed drug delivery system of eyes based on nano-drug delivery strategy has characters of small size, strong penetration, strong surface adhesion for biofilm, and so on, which is expected to develop into a safe, effective, economical and non-invasive new eye drug delivery system, in particular, more and more attention has been paid to drug administration in the posterior eye segment.This paper focuses on the various nano-drug delivery strategies of non-invasive drug administration of the posterior eye segment, including drug delivery systems of nanoparticles, lipidosome, nano-micelle, nano suspensions and nanoemulsion.
引文
[1]Thevi T,Maizura Z,Abas AL.The Melaka Hospital cataract complications study analysis of 12,992 eyes[J].Indian JOphthalmol,2017,65(1):24-29.
[2]Bourne R,Flaxman SR,Braithwaite T,et al.Magnitude,temporal trends,and projections of the global prevalence of blindness and distance and near vision impairment:a systematic review and meta-analysis[J].Lancet Glob Health,2017,5(1):e888-e897.
[3]Janagam DR,Wu L,Lowe TL.Nanoparticles for drug delivery to the anterior segment of the eye[J].Adv Drug Deliv Rev,2017,122(1):31-64.
[4]Thrimawithana TR,Young S,Bunt CR,et al.Drug delivery to the posterior segment of the eye[J].Drug Discov Today,2011,16(5/6):270-277.
[5]Agarwal R,Iezhitsa I,Agarwal P,et al.Liposomes in topical ophthalmic drug delivery:an update[J].Drug Deliv,2016,23(4):1075-1091.
[6]Cholkar K,Patel A,Vadlapudi AD,et al.Novel Nanomicellar Formulation Approache for Anterior and Posterior Segment Ocular Drug Delivery[J].Recent Pat Nanomed,2012,2(2):82-95.
[7]Balguri SP,Adelli GR,Majumdar S.Topical ophthalmic lipid nanoparticle formulations(SLN,NLC)of indomethacin for delivery to the posterior segment ocular tissues[J].Eur J Pharm Biopharm,2016,109:224-235.
[8]Vandamme TF.Microemulsions as ocular drug delivery systems:recent developments and future challenges[J].Prog Retin Eye Res,2002,21(1):15-34.
[9]Abdullah TA,Ibrahim NJ,Warsi MH.Chondroitin sulfatechitosan nanoparticles for ocular delivery of bromfenac sodium:Improved permeation,retention,and penetration[J].Int J Pharm Investig,2016,6(2):96-105.
[10]Fialho SL,Behar-Cohen F,Silva-Cunha A.Dexamethasone-loaded poly(e-caprolactone)intravitreal implants:Apilot study[J].Eur J Pharm Biopharm,2008,68(3):637-646.
[11]Kadam RS,Tyagi P,Edelhauser HF,et al.Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide[J].Int J Pharm,2012,434(1/2):140-147.
[12]Vasconcelos A,Vega E,Perez Y,et al.Conjugation of cell penetrating peptides with poly(lactic-co-glycolicacid)-polyethylene glycol nanoparticales improves ocular drug delivery[J].Int J Nanomedicine,2015,10(2):609-631.
[13]Tahara K,Karasawa K,Onodera R,et al.Feasibility of drug delivery to the eye′s posterior segment by topical instillation of PLGA nanoparticles[J].Asian J Pharm Sci,2017,12(4):394-399.
[14]Wang X,Yu B,Ren W,et al.Topical ophthalmic lipid nanoparticle formulations(SLN,NLC)of indomethacin for delivery to the posterior segment ocular tissues[J].Eur JPharm Biopharm,2013,172(3):690-698.
[15]Sánchez-López E,Espina M,Doktorovova S,et al.Lipid nanoparticles(SLN,NLC):Overcoming the anatomical and physiological barriers of the eye(PartⅡ)Ocular drug-loaded lipid nanoparticles[J].Eur J Pharm Biopharm,2017,110:58-69.
[16]李沙沙,孙朋超,黄维维,等.眼部给药系统研究新进展[J]中国医药工业杂志,2015,46(1):97-104.
[17]蒋敏,甘莉,甘勇,等.新型眼用脂质载体制剂的研究进展[J].中国药学杂志,2012,47(16):1265-1270.
[18]Li N,Zhuang CY,Wang M,et al.Low molecular weight chitosan-coated liposomes for ocular drug delivery:In vitro and in vivo studies[J].Drug Deliv,2012,19(1):28-35.
[19]Zhang J,Liang X,Li X,et al.Ocular delivery of cyanidin-3-glycoside in liposomes and its prevention of selenite-induced oxidative stress[J].Drug Dev Ind Pharm,2016,42(4):546-553.
[20]Fujisawa T,Miyai H,Hironaka K,et al.Liposomal diclofenac eye drop formulations targeting the retina:Formulation stability improvement using surface modification of liposomes[J].Int J Pharm,2012,436(1):564-567.
[21]Davis BM,Normando EM,Guo L,et al.Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes[J].Small,2014,10(8):1575-1584.
[22]Mandal A,Bisht R,Rupenthal ID,et al.Polymeric micelles for ocular drug delivery:From structural frameworks to recent preclinical studies[J].J Control Release,2017,248(1):96-116.
[23]Toshida H,Funaki T,Ono K,et al.Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye:a Japanese PhaseⅡclinical trial[J].Drug Des Develo Ther,2017,11(1):1871-1879.
[24]Patel A,Cholkar K,Agrahari V,et al.Ocular drug delivery systems:An overview[J].World J Pharmacol,2013,2(2):47-64.
[25]Ideta R,Tasaka F,Jang WD,et al.Nanotechnology based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photos ensitizer[J].Nano Lett,2005,5(12):2426-2431.
[26]Ako-Adounvo AM,Nagarwal RC,Oliveira L,et al.Recent Patents on Ophthalmic Nano-formulations and Therapeutic Implications[J].Recent Pat Drug Deliv Formul,2014,8(3):193-201.
[27]Pignatello R,Ricupero N,Bucolo C,et al.Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene[J].AAPS Pharm Sci Tech,2006,7(1):E192-E198.
[28]Baspinar Y,Bertelmann E,Pleyer U,et al.Corneal permeation studies of everolimus microemulsion[J].J Ocul Pharmacol Ther,2008,24(4):399-402.
[29]邓广汉,班俊峰,张彦,等.香豆素-6纳米探针的制备及其眼部给药适应性评价[J].中国医药工业杂志,2016,47(3):305-310.
[30]邵智慧,王健.眼后段给药系统与给药技术[J].世界临床药物,2013,34(7):431-436.
[31]Esther E,Faik O,Yanir A,et al.Charged nanoparticles delivery to the eye using hydrogel iontophoresis[J].JControl Release,2008,126(2):156-161.
[2]Bourne R,Flaxman SR,Braithwaite T,et al.Magnitude,temporal trends,and projections of the global prevalence of blindness and distance and near vision impairment:a systematic review and meta-analysis[J].Lancet Glob Health,2017,5(1):e888-e897.
[3]Janagam DR,Wu L,Lowe TL.Nanoparticles for drug delivery to the anterior segment of the eye[J].Adv Drug Deliv Rev,2017,122(1):31-64.
[4]Thrimawithana TR,Young S,Bunt CR,et al.Drug delivery to the posterior segment of the eye[J].Drug Discov Today,2011,16(5/6):270-277.
[5]Agarwal R,Iezhitsa I,Agarwal P,et al.Liposomes in topical ophthalmic drug delivery:an update[J].Drug Deliv,2016,23(4):1075-1091.
[6]Cholkar K,Patel A,Vadlapudi AD,et al.Novel Nanomicellar Formulation Approache for Anterior and Posterior Segment Ocular Drug Delivery[J].Recent Pat Nanomed,2012,2(2):82-95.
[7]Balguri SP,Adelli GR,Majumdar S.Topical ophthalmic lipid nanoparticle formulations(SLN,NLC)of indomethacin for delivery to the posterior segment ocular tissues[J].Eur J Pharm Biopharm,2016,109:224-235.
[8]Vandamme TF.Microemulsions as ocular drug delivery systems:recent developments and future challenges[J].Prog Retin Eye Res,2002,21(1):15-34.
[9]Abdullah TA,Ibrahim NJ,Warsi MH.Chondroitin sulfatechitosan nanoparticles for ocular delivery of bromfenac sodium:Improved permeation,retention,and penetration[J].Int J Pharm Investig,2016,6(2):96-105.
[10]Fialho SL,Behar-Cohen F,Silva-Cunha A.Dexamethasone-loaded poly(e-caprolactone)intravitreal implants:Apilot study[J].Eur J Pharm Biopharm,2008,68(3):637-646.
[11]Kadam RS,Tyagi P,Edelhauser HF,et al.Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide[J].Int J Pharm,2012,434(1/2):140-147.
[12]Vasconcelos A,Vega E,Perez Y,et al.Conjugation of cell penetrating peptides with poly(lactic-co-glycolicacid)-polyethylene glycol nanoparticales improves ocular drug delivery[J].Int J Nanomedicine,2015,10(2):609-631.
[13]Tahara K,Karasawa K,Onodera R,et al.Feasibility of drug delivery to the eye′s posterior segment by topical instillation of PLGA nanoparticles[J].Asian J Pharm Sci,2017,12(4):394-399.
[14]Wang X,Yu B,Ren W,et al.Topical ophthalmic lipid nanoparticle formulations(SLN,NLC)of indomethacin for delivery to the posterior segment ocular tissues[J].Eur JPharm Biopharm,2013,172(3):690-698.
[15]Sánchez-López E,Espina M,Doktorovova S,et al.Lipid nanoparticles(SLN,NLC):Overcoming the anatomical and physiological barriers of the eye(PartⅡ)Ocular drug-loaded lipid nanoparticles[J].Eur J Pharm Biopharm,2017,110:58-69.
[16]李沙沙,孙朋超,黄维维,等.眼部给药系统研究新进展[J]中国医药工业杂志,2015,46(1):97-104.
[17]蒋敏,甘莉,甘勇,等.新型眼用脂质载体制剂的研究进展[J].中国药学杂志,2012,47(16):1265-1270.
[18]Li N,Zhuang CY,Wang M,et al.Low molecular weight chitosan-coated liposomes for ocular drug delivery:In vitro and in vivo studies[J].Drug Deliv,2012,19(1):28-35.
[19]Zhang J,Liang X,Li X,et al.Ocular delivery of cyanidin-3-glycoside in liposomes and its prevention of selenite-induced oxidative stress[J].Drug Dev Ind Pharm,2016,42(4):546-553.
[20]Fujisawa T,Miyai H,Hironaka K,et al.Liposomal diclofenac eye drop formulations targeting the retina:Formulation stability improvement using surface modification of liposomes[J].Int J Pharm,2012,436(1):564-567.
[21]Davis BM,Normando EM,Guo L,et al.Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes[J].Small,2014,10(8):1575-1584.
[22]Mandal A,Bisht R,Rupenthal ID,et al.Polymeric micelles for ocular drug delivery:From structural frameworks to recent preclinical studies[J].J Control Release,2017,248(1):96-116.
[23]Toshida H,Funaki T,Ono K,et al.Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye:a Japanese PhaseⅡclinical trial[J].Drug Des Develo Ther,2017,11(1):1871-1879.
[24]Patel A,Cholkar K,Agrahari V,et al.Ocular drug delivery systems:An overview[J].World J Pharmacol,2013,2(2):47-64.
[25]Ideta R,Tasaka F,Jang WD,et al.Nanotechnology based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photos ensitizer[J].Nano Lett,2005,5(12):2426-2431.
[26]Ako-Adounvo AM,Nagarwal RC,Oliveira L,et al.Recent Patents on Ophthalmic Nano-formulations and Therapeutic Implications[J].Recent Pat Drug Deliv Formul,2014,8(3):193-201.
[27]Pignatello R,Ricupero N,Bucolo C,et al.Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene[J].AAPS Pharm Sci Tech,2006,7(1):E192-E198.
[28]Baspinar Y,Bertelmann E,Pleyer U,et al.Corneal permeation studies of everolimus microemulsion[J].J Ocul Pharmacol Ther,2008,24(4):399-402.
[29]邓广汉,班俊峰,张彦,等.香豆素-6纳米探针的制备及其眼部给药适应性评价[J].中国医药工业杂志,2016,47(3):305-310.
[30]邵智慧,王健.眼后段给药系统与给药技术[J].世界临床药物,2013,34(7):431-436.
[31]Esther E,Faik O,Yanir A,et al.Charged nanoparticles delivery to the eye using hydrogel iontophoresis[J].JControl Release,2008,126(2):156-161.